Fed. Circ. Iffy On Alvogen's Bid To Unblock Generic Opioid
By Britain Eakin ( November 1, 2022, 6:52 PM EDT) -- An attorney for Alvogen met some stiff resistance on Tuesday from a Federal Circuit panel that grilled him over the company's bid to kill claims in two BioDelivery Sciences patents on the opioid drug Belbuca to clear the way for a proposed generic....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.